Alpha Teknova, Inc. (TKNO) Stock Price & Analysis
Alpha Teknova, Inc. (TKNO) closed at USD 7.86 on Wednesday, October 28, 2026, up 10.55% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 7.11; the Oct 28, 2026 session ranged USD 6.94–7.89 on volume of 951,240 shares. Market capitalization is $484.98M, with a 52-week range of USD 1.91–9.48 (NGM). Source: Nexqual, retrieved October 29, 2026 at 00:17 UTC.
Also available as compact Markdown for AI agents: nexqual.com/TKNO.md
Key facts (TKNO)
- Last four reported quarters (through Jun 30, 2026): revenue $43.7M, net income -$16.8M (-38.4% margin), free cash flow -$7.4M (SEC filings).
- Analysts: Buy (mean 2.13 on a 1–5 scale) (8 analysts), mean target USD 9.67 (range 8–12).
- Total return with dividends: 1Y +32.2% vs S&P 500 +13.2%; 5Y -65.8% vs S&P 500 +79.8%.
- Next earnings: 2026-11-04, EPS estimate USD -0.07, revenue estimate $11.8M.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (TKNO)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $36.9M | $41.4M | $36.7M | $37.7M | $40.5M | $43.7M |
| Gross profit | $17.6M | $17.5M | $10.3M | $7.2M | $13.4M | — |
| Operating income | -$12.0M | -$49.7M | -$35.6M | -$26.1M | -$17.0M | -$15.8M |
| Net income | -$9.8M | -$47.5M | -$36.8M | -$26.7M | -$17.3M | -$16.8M |
| EPS (diluted) | -$0.61 | -$1.69 | -$1.16 | -$0.57 | -$0.32 | — |
| Free cash flow | -$28.9M | -$55.5M | -$26.7M | -$13.5M | -$9.8M | -$7.4M |
| Gross margin | 47.8% | 42.2% | 28.1% | 19.2% | 33.2% | — |
| Operating margin | -32.5% | -119.9% | -96.9% | -69.3% | -41.9% | -36.2% |
| Net margin | -26.6% | -114.6% | -100.3% | -70.9% | -42.6% | -38.4% |
| Revenue growth | +17.9% | +12.3% | -11.4% | +2.9% | +7.4% | — |
| Cash + short-term investments | $87.5M | — | $28.5M | $30.4M | $21.3M | — |
| Total debt | $11.9M | $22.0M | $13.3M | $13.5M | $13.1M | — |
Fiscal years end Dec. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (TKNO)
P/S 11.1x · EV/Sales 11.0x · P/B 7.8x · FCF yield -1.52% · Earnings yield -3.46% · Net cash $4.2M · EV $481M
Analysts (TKNO)
Consensus Buy (mean 2.13 on a 1–5 scale), 8 analysts; mean target USD 9.67 (low 8, high 12).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-13 | TD Cowen | Target raised | Buy | $7 → $11 |
| 2026-09-17 | Jefferies | Initiated | Buy | $9 |
| 2026-08-11 | BTIG | Upgrade | Neutral → Buy | $8 |
| 2026-08-05 | Roth Capital | Initiated | Buy | $7 |
Total return (dividends reinvested) (TKNO)
| 1Y (from 2025-10-29) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +32.2% | -65.8% |
| S&P 500 (SPY) | +13.2% | +79.8% |
| Per year | +32.4% | -19.3% |
| Volatility (annualized) | 79.7% | 94.6% |
| Max drawdown | -63.0% (Oct 2025→Feb 2026) | -95.5% (Nov 2021→Jul 2024) |
TKNO earnings history and stock reaction
| Results filed | Quarter | EPS | Consensus | Surprise | Stock reaction |
|---|---|---|---|---|---|
| Oct 21, 2026 | — | — | — | — | -16.8% |
| Aug 5, 2026 | Quarter ended Jun 30, 2026 | −$0.05 | −$0.07 | Beat +28.6% | +18.3% |
| May 6, 2026 | Quarter ended Mar 31, 2026 | −$0.08 | −$0.09 | Beat +11.1% | +7.0% |
| Feb 26, 2026 | Quarter ended Dec 31, 2025 | −$0.09 | −$0.09 | In line | +14.2% |
| Nov 6, 2025 | Quarter ended Sep 30, 2025 | −$0.08 | −$0.09 | Beat +11.1% | -4.8% |
| Aug 7, 2025 | — | — | — | — | -2.8% |
| May 8, 2025 | — | — | — | — | +16.2% |
| Mar 4, 2025 | — | — | — | — | +1.9% |
EPS as reported against the analyst consensus before the release; surprise uses the cent-rounded figures shown (in dollars when EPS and consensus have opposite signs). Stock reaction = close before the results to close after (the first close following a release after the bell or before the open).
TKNO recent SEC filings (last 120 days)
| Filed | Form | What it says |
|---|---|---|
| Oct 21, 2026 | 8-K | Entered a material agreement; Quarterly results; Other material event “On October 20, 2026, Alpha Teknova, Inc. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with TD Securities (USA) LLC and William Blair & Company, L.L.C. as the representatives of the several underwriters named therein (the "Underwriters"), relating to an underwritten public offering (the "Offering") of an aggregate of 8,000,000 shares of the Company's common stock ("Common Stock"). The public offering price is $5.00 per share of Common Stock and the Underwriters have agreed…” |
| Aug 6, 2026 | 10-Q | Quarterly report · period ended Jun 30, 2026 |
| Aug 5, 2026 | 8-K | Quarterly results |
Source: SEC EDGAR. Quotes are the opening words of each item as filed; each form links to the filing. Insider Form 4 filings are listed in the insider sections.
TKNO revenue by product line (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| Lab Essentials | $9.2M | 75.4% | +17.9% |
| Clinical Solutions | $2.4M | 19.9% | +17.9% |
| Other Product | $573,000 | 4.7% | +31.7% |
| Total revenue | $12.2M | 100% | — |
TKNO revenue by region (quarter ended Jun 30, 2026)
| Line | Revenue | Share of total | YoY |
|---|---|---|---|
| United States | $11.7M | 95.7% | +19.2% |
| Non Us | $526,000 | 4.3% | +3.1% |
| Total revenue | $12.2M | 100% | — |
As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).
TKNO suppliers, customers and competitors (named in its 10-K)
| Relationship | Company | Sentence in the filing |
|---|---|---|
| Customer | FedEx (FDX) | “We ship a significant portion of our products to our customers through independent package delivery companies, such as FedEx, UPS, and FedEx Freight.” |
| Customer | UPS (UPS) | “We ship a significant portion of our products to our customers through independent package delivery companies, such as FedEx, UPS, and FedEx Freight.” |
| Competitor | Thermo Fisher (TMO) | “Our Lab Essentials and Clinical Solutions products compete, based on turnaround time, performance, and quality, with products offered by numerous large, established life science companies such as Thermo Fisher, Millipore (Merck KGaA), Cytiva (Danaher), and Hardy Diagnostics, as well as smaller, companies such as GeminiBio, Boston BioProducts, and Biologos.” |
| Competitor | Merck (MRK) | “Our Lab Essentials and Clinical Solutions products compete, based on turnaround time, performance, and quality, with products offered by numerous large, established life science companies such as Thermo Fisher, Millipore (Merck KGaA), Cytiva (Danaher), and Hardy Diagnostics, as well as smaller, companies such as GeminiBio, Boston BioProducts, and Biologos.” |
Quoted from the company's 10-K filed Mar 2, 2026.
TKNO company outlook (results filed Oct 21, 2026)
- “Private Securities Litigation Reform Act of 1995, including statements regarding Teknova's expectations on the timing, size and completion of the proposed offering, Teknova's intention to grant the underwriters a 30-day option to purchase additional shares, and the anticipated use of proceeds therefrom.”
Quoted word-for-word from the SEC 8-K results press release.
TKNO analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $-0.07 | $-0.08 | +$0.01 | $11.8M | 4 |
| Next quarter (ends Dec 2026) | $-0.08 | $-0.09 | +$0.01 | $11.1M | 4 |
| Current fiscal year (ends Dec 2026) | $-0.29 | $-0.34 | +$0.05 | $46.0M | 4 |
| Next fiscal year (ends Dec 2027) | $-0.19 | $-0.20 | +$0.01 | $52.7M | 1 |
TKNO options: expected move
Options price a move of about ±9.4% (±$0.72) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±10.3% on average.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 23 | 96.1% | ±9.4% |
| Dec 18, 2026 | 51 | 91.8% | ±28.3% |
| Mar 19, 2027 | 142 | 91.5% | ±44.8% |
30-day implied volatility 79.4% vs 95.5% realized over the last 30 trading days. Put/call ratio (volume) 0.17. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 29, 2026 at 00:17 UTC)
| Price | USD 7.86 |
|---|---|
| Change | ▲ 10.55% (up) |
| Previous Close | USD 7.11 |
| Open | USD 7.11 |
| Day Range | USD 6.94 – 7.89 |
| 52-Week Range | USD 1.91 – 9.48 |
| Volume | 951,240 shares |
| Market Cap | $484.98M |
| Exchange | NGM |
Technical Analysis (TKNO)
Nexqual's technical model rates TKNO "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of October 29, 2026 at 00:17 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 47.9 (neutral) |
| vs SMA50 | Above (USD 7.67) |
| MACD | -0.39 (negative) |
Analyst Ratings (TKNO)
Wall Street analysts rate TKNO "Buy" based on 8 analysts, with a mean price target of USD 9.67 (range USD 8–12), per Nexqual as of October 29, 2026 at 00:17 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 8 |
| Mean Target | USD 9.67 |
| High Target | USD 12 |
| Low Target | USD 8 |
| Buy / Hold / Sell | 7 / 1 / 0 |
Earnings (TKNO)
| Next Earnings Date | 2026-11-04 |
|---|---|
| Revenue Estimate | $11.77M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.05 vs est -0.07 ▲ beat |
| 2026-03-31 | USD -0.08 vs est -0.09 ▲ beat |
| 2025-12-31 | USD -0.09 vs est -0.09 ▲ beat |
| 2025-09-30 | USD -0.08 vs est -0.09 ▲ beat |
Source: Nexqual, October 29, 2026 at 00:17 UTC.
Financials & Fundamentals (TKNO)
| Total Revenue | $43.70M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +18.50% |
| Gross Margin | +34.60% |
| Operating Margin | -23.72% |
| Profit Margin | -38.37% |
| ROE | -24.19% |
| Debt / Equity | 0.44 |
| Current Ratio | 4.49 |
| Total Cash | $17.44M |
| Total Debt | $27.41M |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | -$7.35M (-16.8% of revenue) |
Source: Nexqual, October 29, 2026 at 00:17 UTC.
Financial Health Score (TKNO)
Nexqual rates Alpha Teknova, Inc.'s overall financial health "Weak" across five dimensions, as of October 29, 2026 at 00:17 UTC.
| Growth | Solid — Revenue +7% YoY (annual) |
|---|---|
| Profitability | Weak — Not yet profitable — scaling phase |
| Balance Sheet | Strong — $17M cash and investments vs $13M debt (Jun 2026, SEC), net cash |
| Cash Flow | Weak — FCF negative: -$7M (last 4 quarters to Jun 2026, SEC), burning cash |
| Efficiency | Critical — ROE -27%, ROA -17.5% (last 4 quarters, SEC) |
Ownership (TKNO)
| Insider Ownership | +8.10% |
|---|---|
| Institutional Ownership | +76.00% |
| Shares Outstanding | 61.70M |
| Float | 16.54M |
| Short % of Float | +14.99% |
Source: Nexqual, October 29, 2026 at 00:17 UTC.
Leadership (TKNO)
Alpha Teknova, Inc. is led by Stephen Gunstream, President, CEO & Director, per Nexqual as of October 29, 2026 at 00:17 UTC.
| President, CEO & Director | Stephen Gunstream |
|---|---|
| Chief Financial Officer | Matthew C. Lowell |
| Senior Vice President of Marketing | Jennifer Henry |
Major Backers & Investors (TKNO)
Notable institutional backers of Alpha Teknova, Inc. include Royce & Associates LP, Roubaix Capital, LLC, ROYCE MICRO-CAP TRUST, INC.-Royce Micro-Cap Trust Inc, according to Nexqual as of October 29, 2026 at 00:17 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Royce & Associates LP | 3.09% |
| Roubaix Capital, LLC | 2.94% |
| ROYCE MICRO-CAP TRUST, INC.-Royce Micro-Cap Trust Inc | 1.94% |
| UBS Group AG | 1.18% |
| ROYCE FUND-Royce Micro-Cap Fund | 0.87% |
| Conestoga Capital Advisors, LLC | 0.59% |
| Bank of America Corporation | 0.48% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 3.01% |
| BlackRock | 1.64% |
| Geode Capital | 0.58% |
Source: Nexqual, October 29, 2026 at 00:17 UTC.
From Alpha Teknova, Inc.'s Latest SEC 10-K Filing (filed 2026-03-02)
Key Strengths & Strategy (as disclosed to the SEC)
- Our proprietary capabilities and products underpin the value we provide to customers across their product development and commercialization activities and allow us to scale with our clients as they grow, supporting their need for materials in greater volumes and that meet increasingly stringent regulatory requirements.
- Our more than 3,000 customers span the continuum of the life sciences market and include leading pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostics franchises, and academic and government research institutions.
- We leverage our proprietary chemical formulation and production expertise, supported by a product database consisting of the formulations of thousands of previously made products.
- Our operations, built upon our proprietary manufacturing processes developed over 30 years, enable adaptable, versatile, and rapid production of complex chemical formulations.
Legal & Regulatory Risks (Item 1A, quoted)
- Product liability lawsuits against us could cause us to incur substantial liabilities, limit sales of our existing products, and limit commercialization of any products that we may develop.
- We are subject to stringent and evolving data privacy and information security laws, regulations, and standards, as well as policies and contractual obligations related to data privacy and security, and changes in these could adversely affect our business.
- Changes in political, economic, or governmental regulations may reduce demand for our products or increase our expenses.
- Changes in the state and local regulatory environment could limit our business activities or increase our operating costs.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SUPN | Supernus Pharmaceuticals, Inc. | USD 41.08 | ▲ 0.29% |
| BHC | Bausch Health Companies Inc. | USD 6.92 | ▲ 9.67% |
| AMLX | Amylyx Pharmaceuticals, Inc. | USD 28.07 | ▼ 0.81% |
| RGC | Regencell Bioscience Holdings L | USD 7.27 | ▼ 2.55% |
| LQDA | Liquidia Corporation | USD 45.72 | ▲ 0.62% |
| INDV | Indivior Pharmaceuticals, Inc. | USD 34.77 | ▲ 0.14% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 29, 2026 at 00:17 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt